EDEN PRAIRIE, Minn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that CEO Jeff Ross will present at the 2022 Cell & Gene Meeting on the Mesa. The three day event held this year on October 11-13 features in-person and pre-recorded virtual presentations by leading public and private companies highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and regenerative medicine.
Mr. Ross will deliver his remarks at the 2022 Cell & Gene Meeting on the Mesa in the Oxford Biomedica Ballroom on October 12th, 2022 at 6:30 pm ET. Registration for the conference is available here.
Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.